Eli Lil­ly’s mi­graine pre­ven­tion drug Em­gal­i­ty not su­pe­ri­or to Pfiz­er’s Nurtec ODT in head-to-head

In a head-to-head clin­i­cal tri­al, Eli Lil­ly’s in­jectable mi­graine drug Em­gal­i­ty was not su­pe­ri­or to the Nurtec ODT tablets out of Pfiz­er on a pri­ma­ry …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.